Evidence map›Paper›PMID 40531570›Full record

ArticleJMIR research protocols2025

Improving HIV Prevention Among Heterosexual Men Seeking Sexually Transmitted Infection Services in Malawi: Protocol for a Type I Effectiveness-Implementation Hybrid Randomized Controlled Trial of Systems Navigator-Delivered Integrated Prevention Package (HPTN 112-NJIRA Study).

Sarah E Rutstein, Laura Limarzi-Klyn, Jane S Chen, Yaw O Agyei, Shahnaz Ahmed, Ian Bell, Myron Cohen, Jessica M Fogel, Vivian Go, Dan Haines and 10 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06200545 (Improving HIV Prevention Among Heterosexual Men Seeking STI Services in Malawi), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06200545 nacompletednot on this map

Improving HIV Prevention Among Heterosexual Men Seeking STI Services in Malawi: Examining the Benefits, Acceptability, and Associated Costs of a Systems-navigator-delivered Integrated Prevention Package

TypeinterventionalSponsorHIV Prevention Trials NetworkRan2024 to 2025Enrolled199ConditionsHIV Infection, Sexually Transmitted Infections, Pre-exposure Prophylaxis, Systems NavigationArmsPrEP eligibility assessment, Rapid HIV antibody testing prior to provision and/or refill of PrEP, PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines, Evaluation of barriers and facilitators to ongoing PrEP use, Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sarah E RutsteinDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0002-1571-6576
Laura Limarzi-KlynDepartment of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0009-0003-8427-3347
Jane S ChenDepartment of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0001-7648-0651
Yaw O AgyeiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID 0000-0001-5614-4108
Shahnaz AhmedDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID 0000-0002-7979-889X
Ian BellUniversity of Washington, Department of Biostatistics, HPTN Statistical and Data Management Center, Seattle, WA, United States.ORCID 0009-0006-7708-235X
Myron CohenDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0001-5917-9664
Jessica M FogelDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID 0000-0003-3143-9000
Vivian GoDepartment of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0003-4828-6880
Dan HainesUniversity of Washington, Department of Biostatistics, HPTN Statistical and Data Management Center, Seattle, WA, United States.ORCID 0009-0003-7001-0845
Erica L HamiltonNetwork and Collaborative Research Division, FHI 360, Durham, NC, United States.ORCID 0000-0003-1174-9263
Irving F HoffmanDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0003-0059-5991
Mina C HosseinipourDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0003-2174-313X
Mark A MarzinkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.ORCID 0000-0003-1670-8786
William C MillerDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.ORCID 0000-0002-1934-7827
Mathews MukatipaUNC Project Malawi, Lilongwe, Malawi.ORCID 0000-0003-4825-0810
Julie PulerwitzPopulation Council, Washington, DC, United States.ORCID 0000-0001-5177-1508
Hans M L SpiegelKelly Government Solutions, Contractor to National Institute of Allergy and Infectious Diseases, National Institutes of Health, HHS, Rockville, MD, United States.ORCID 0000-0001-9552-789X
Ting YeUniversity of Washington, Department of Biostatistics, HPTN Statistical and Data Management Center, Seattle, WA, United States.ORCID 0000-0001-6009-641X
Mitch MatogaUNC Project Malawi, Lilongwe, Malawi.ORCID 0000-0002-6542-8193

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
NIAID NIH HHS P30 AI050410NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069423
6 · The paper itself

Abstract

backgroundPreexposure prophylaxis (PrEP) remains one of the most efficacious interventions for preventing HIV, but its effectiveness is often limited by poor persistence. Although regional efforts have primarily focused on young women and men who have sex with men, heterosexual men in East and Southern Africa represent a crucial group to engage and retain in PrEP care-both to improve health outcomes for men and to interrupt HIV transmission chains. Men seeking sexually transmitted infection (STI) services are particularly vulnerable to HIV acquisition, yet only a few interventions have tested strategies for engaging and retaining these men in PrEP services. Systems navigation, which addresses barriers to health care access and enhances comfort in clinical settings, may offer a promising approach to improving persistent PrEP use among heterosexual men.

objectiveThis study will assess the effect of a peer-delivered systems navigator-facilitated HIV prevention package on PrEP persistence at 26 weeks among heterosexual men seeking STI clinical services in Lilongwe, Malawi. It will also evaluate the acceptability of the intervention and barriers to implementation among key stakeholders. Insights will inform the feasibility of a future randomized controlled trial.

methodsIn this single-site pilot type I effectiveness-implementation hybrid randomized controlled trial, 200 heterosexual men seeking STI services and initiated on PrEP in Lilongwe, Malawi, will be randomized (1:2) to standard-of-care PrEP services or systems navigator-assisted PrEP care (intervention). Participants will be followed every 13 weeks for at least 26 and up to 52 weeks. PrEP use and engagement in care will be assessed through medical record review and intraerythrocytic tenofovir diphosphate measurement, using objective biomedical analyses via dried blood spot. Primary effectiveness and implementation outcomes include 26-week PrEP persistence (adapted to accommodate daily oral, event-driven oral, or injectable PrEP) and acceptability, respectively. Additional implementation outcomes include feasibility and cost. Exploratory objectives characterize preferences for PrEP modalities, perceived and experienced stigma, and the influence of gender norms on PrEP persistence. All clinical services, including the provision of PrEP and PrEP safety monitoring, are being conducted by the Malawi Ministry of Health.

resultsHPTN (HIV Prevention Trials Network) 112 was funded in November 2023. Study recruitment began in April 2024 and closed in November 2024. As of February 3, 2025, the study has enrolled 199 participants, with follow-up expected through June 2025. No interim analyses were planned; data analysis for primary end points is expected in the summer of 2025.

conclusionsImproving PrEP use outcomes among heterosexual men in East and Southern Africa is critical to interrupting HIV transmission. This study offers unique insights into a low-resource, potentially scalable intervention, focusing on a group of men at particularly high risk of HIV acquisition-those with recent STIs. The hybrid RCT design addresses clinically relevant effectiveness questions and explores key determinants that will inform future multisite implementation trials.

trial registrationClinicalTrials.gov NCT06200545; https://clinicaltrials.gov/study/NCT06200545. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/72981.

Indexed as

HeterosexualityHIV InfectionsPre-Exposure ProphylaxisSexually Transmitted DiseasesAdultAnti-HIV AgentsHumansMalawiMaleRandomized Controlled Trials as TopicYoung AdultAnti-HIV Agentsbacterial STIheterosexualHIV preventionhybridlong-acting injectablepeerpreexposure prophylaxis

Identifiers

PMID40531570
PMCPMC12223453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.